Hepatitis C
AbbVie Interferon-free Hepatitis C Combo Gets FDA 'Breakthrough' Status
- Details
- Category: HCV Treatment
- Published on Tuesday, 07 May 2013 00:00
An all-oral regimen of 3 new direct-acting antiviral agents, with or without ribavirin, has been designated by the U.S. Food and Drug Administration (FDA) as a "breakthrough therapy" for people with genotype 1 chronic hepatitis C, AbbVie (formerly Abbott) announced this week.
CDC: Hepatitis C Testing Requires Both Antibody Screening and HCV RNA Follow-up
- Details
- Category: HCV Testing & Diagnosis
- Published on Tuesday, 07 May 2013 00:00
Half of all people who receive an initial hepatitis C virus (HCV) antibody screening test never return for follow-up viral load testing to determine if they are still infected, according to a recent Centers for Disease Control and Prevention (CDC) study. Confirmatory testing is needed to link people with chronic hepatitis C to appropriate care and treatment. "You may not remember what you did in the 60s and 70s," said CDC director Thomas Frieden,"but your liver does."
EASL 2013: Sofosbuvir + Interferon/Ribavirin Cures 90% of People with Hard-to-Treat HCV Genotypes
- Details
- Category: HCV Treatment
- Published on Friday, 03 May 2013 00:00
Adding the second-generation HCV polymerase inhibitor sofosbuvir (formerly GS-7977) to pegylated interferon plus ribavirin led to a sustained response rate of 89% for treatment-naive patients with HCV genotype 1 in the NEUTRINO study, researchers reported at the EASL International Liver Congress(EASL 2013) last week in Amsterdam. High rates were also seen for the less common genotypes 4, 5 and 6.
EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients
- Details
- Category: HCV Treatment
- Published on Friday, 03 May 2013 00:00
European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at the EASL International Liver Congress (EASL 2013) in Amsterdam last week. However, clear differences in opinion emerged between patients and doctors regarding who should make decisions about acceptable levels of risk to patients during a symposium on compassionate use organized by the European Liver Patients Association.
EASL 2013: Daclatasvir + Asunaprevir + BMS-791352 Looks Promising as Interferon-free Combo
- Details
- Category: HCV Treatment
- Published on Wednesday, 01 May 2013 00:00
An all-oral regimen containing 3 next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1 chronic hepatitis C patients in a Phase 2a study, according to a late-breaking poster presentation at the EASL International Liver Congress(EASL 2013) in Amsterdam.
EASL 2013: HCV Protease Inhibitor Simeprevir Pushes Triple Therapy Cure Rate Up to 80%
- Details
- Category: HCV Treatment
- Published on Friday, 03 May 2013 00:00
A second-generation HCV protease inhibitor, simeprevir (formerly TMC435), cured around 80% of previously untreated people with genotype 1 hepatitis C infection when combined with pegylated interferon and ribavirin, Michael Manns of the University of Hannover Medical School reported last week at the EASL International Liver Congress (EASL 2013) in Amsterdam. Overall, 91% of simeprevir-treated patients able to stop all treatment after 24 weeks.
EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
Currently available triple therapies for hepatitis C using HCV protease inhibitors carry a high risk of serious side effects for patients in the most urgent need of treatment, and these individuals have only a moderate chance of being cured, according to findings from studies of telaprevir and boceprevir treatment in cirrhotic patients at liver centers in France and Austria reported last week at the 48th International Liver Congress in Amsterdam. In the Austrian study almost 1 in 10 cirrhotic patients were hospitalized with sepsis during triple therapy.
EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Friday, 03 May 2013 00:00
Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, according to results from the COMMAND study reported last week at the EASL International Liver Congress(EASL 2013) in Amsterdam. People with genotype 3, however, did not respond as well as those with genotype 2.
EASL 2013: Hep C Quad Regimens Quashed, but Some Components Go Forward
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
A pair of 4-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a set of presentations last week at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. While this type of quad regimen has little if any future, some of the component drugs remain promising.
More Articles...
- EASL 2013: Second-generation Protease Inhibitor Faldaprevir Cures up to 80% of Genotype 1 Hepatitis C
- EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- EASL 2013: MK-5172 Boosts Interferon/Ribavirin Response Regardless of IL28B Status
- EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
- EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1
Web Design and Development by